A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort

Bladder cancer (BCa) is among the most commonly diagnosed malignancies worldwide, and due the high rate of post-operative disease recurrence, it is one of the most prevalent in many countries. The development of non-invasive molecular assays that can accurately detect and monitor BCa would be a majo...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of translational medicine 2016-10, Vol.14 (1), p.287-287, Article 287
Main Authors:	Goodison, Steve, Ogawa, Osamu, Matsui, Yoshiyuki, Kobayashi, Takashi, Miyake, Makito, Ohnishi, Sayuri, Fujimoto, Kiyohide, Dai, Yunfeng, Shimizu, Yoshiko, Tsukikawa, Kazue, Furuya, Hideki, Rosser, Charles J
Format:	Article
Language:	eng
Subjects:	Adult Aged Aged, 80 and over Apolipoproteins Asian Continental Ancestry Group Biological markers Biomarkers, Tumor - urine Bladder cancer Care and treatment Cohort Studies Demography Diagnosis Enzyme-Linked Immunosorbent Assay Female Health aspects Humans Immunoassay - methods Male Middle Aged ROC Curve Sensitivity and Specificity Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - urine Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Bladder cancer (BCa) is among the most commonly diagnosed malignancies worldwide, and due the high rate of post-operative disease recurrence, it is one of the most prevalent in many countries. The development of non-invasive molecular assays that can accurately detect and monitor BCa would be a major advance, benefiting both patients and healthcare systems. We have previously identified a urinary protein biomarker panel that is being developed for application in at-risk patient cohorts. Here, we investigated the potential utility of the multiplex assay in a Japanese cohort. The Japanese study cohort collected from urology clinics at two institutions was comprised of a total of 288 subjects. The protein biomarker panel (IL8, MMP9, MMP10, ANG, APOE, SDC1, A1AT, PAI1, CA9, VEGFA) was monitored in voided urine samples collected prior to cystoscopy using a custom multiplex ELISA assay. The diagnostic performance of the biomarker panel was assessed using receiver operator curves, predictive modeling and descriptive statistics. Urinary biomarker concentrations were significantly elevated in cases versus controls, and in cases with high-grade and muscle-invasive tumors. The AUC for the 10-biomarker assay was 0.892 (95 % confidence interval 0.850-0.934), with an overall diagnostic sensitivity specificity of 0.85 and 0.81, respectively. A predictive model trained on the larger institutional cohort correctly identified 99 % of the cases from the second institution. Urinary levels of a 10-biomarker panel enabled discrimination of patients with BCa. The multiplex urinary diagnostic assay has the potential to be developed for the non-invasive detection of BCa in at-risk Japanese patients.
ISSN:	1479-5876 1479-5876